Cortical excitability reduction

Cortical excitability reduction refers to a physiological state characterized by a decreased propensity for cortical neurons to generate action potentials in response to excitatory stimuli. It is not a singular molecular target but rather a macroscopic therapeutic endpoint resulting from the modulation of various receptors and ion channels, most notably GABA-A receptors, glutamate receptors, and voltage-gated sodium/calcium channels (Rossini et al., 2015, Clinical Neurophysiology). This phenomenon is a primary objective in the treatment of neurological disorders defined by neuronal hyperexcitability, such as epilepsy, where reducing excitability prevents the initiation and propagation of seizures, and migraine, where it limits the spread of cortical spreading depression (Stahl, 2013, Essential Psychopharmacology).\n\nClinically, cortical excitability is assessed using Transcranial Magnetic Stimulation (TMS), which measures the responsiveness of the motor cortex through biomarkers like the Resting Motor Threshold (RMT) and Motor Evoked Potential (MEP) amplitude. Drugs that successfully induce cortical excitability reduction often demonstrate efficacy in stabilizing neural networks, though they carry inherent safety risks such as sedation and cognitive slowing due to their broad impact on central nervous system signaling. Understanding this physiological parameter is crucial for drug developers focusing on neuroprotection and the management of paroxysmal brain disorders.

Other names

Neuronal excitability reductionCortical inhibition enhancementSuppression of cortical hyperexcitabilityDecreased cortical responsiveness

Cortical excitability reduction is achieved through the integrated modulation of multiple molecular targets that shift the balance toward inhibitory neurotransmission. Key mechanisms include the positive allosteric modulation of GABA-A receptors (enhancing Cl- conductance), the blockade of voltage-gated sodium channels (preventing repetitive firing), the inhibition of glutamate receptors like NMDA or AMPA (reducing excitatory input), and the modulation of calcium channels or SV2A protein to decrease neurotransmitter release.